GVR Report cover Muscle Relaxant Drugs Market Size, Share & Trends Report

Muscle Relaxant Drugs Market Size, Share & Trends Analysis Report By Drug Type (Facial Muscle Relaxants, Skeletal Muscle Relaxants, Neuromuscular Blocking Agents), By Distribution Channel, By Region, And Segment Forecasts, 2022 To 2030

  • Report ID: GVR453615
  • Number of Pages: 0
  • Format: Electronic (PDF)

The market is witnessing an increase in the use of relaxant drugs to treat muscle spasticity or spasms. This can be attributed due to the growing geriatric population with musculoskeletal disorders, the rising number of surgical procedures, sedentary lifestyle leading to back pain, work-related musculoskeletal disorders, and other factors leading to an increase in demand for such agents. For instance, according to an Elsevier article, a December 2021 research found that 64% of healthcare workers had a work-related musculoskeletal disease, with lower back pain being the most frequent complaint. Thus, the rising prevalence of such conditions is offering a lucrative opportunity for growth in the muscle relaxant drugs market.

The market has been segmented by drug type:

  • Facial Muscle Relaxants

  • Skeletal Muscle Relaxants

  • Neuromuscular Blocking Agents

The space has presence of a diverse group of medications in the management of condition. This includes three FDA-approved drugs baclofen, tizanidine, and dantrolene to treat spasticity, and six FDA-approved drugs carisoprodol, metaxalone, methocarbamol, chlorzoxazone, orphenadrine, and cyclobenzaprine indicated to treat muscular spasms. Botulinum toxin is another approved drug for spasticity but is used only for a certain group of cases.

Key market players are developing novel therapies and launching new products and generics in the muscle relaxant drugs market. For instance, in July 2021, Hikma Pharmaceuticals Plc. announced the launch of 20mg/ml Succinylcholine Chloride Injection indicated for skeletal muscle relaxation associated with surgery or mechanical ventilation in the U.S. Such neuromuscular blocking agents (example: succinylcholine, doxacurium, Cisatracurium, and rocuronium) are important during surgeries. In January 2022, Amneal Pharmaceuticals announced the successful acquisition of Saol's Baclofen franchise to enhance the company’s product portfolio with the Lioresal, Lyvispah, and clinical products in the segment.

Muscle Relaxant Drugs Market Segmentation



Drug Type

Facial Muscle Relaxants, Skeletal Muscle Relaxants, And Neuromuscular Blocking Agents

Distribution Channel

Hospital pharmacies, Retail pharmacies, Others


North America; Europe; Asia Pacific; Latin America; Middle East and Africa (MEA)


Major companies operating in the market include Pfizer, Inc., Teva Pharmaceuticals Industries Ltd., Hikma Pharmaceuticals, Zydus Cadila, Ipsen Biopharmaceuticals Inc., Neurana Pharmaceuticals, and Amneal Pharmaceuticals amongst others.

gvr icn


gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

gvr icn


We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

esomar icon

ESOMAR certified & member

D&B icon

Leading SME award by D&B

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.

great place to work icon